#nasdaq:shpg

SHIRE PLC (NASDAQ:SHPG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SHIRE PLC (NASDAQ:SHPG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Item 5.02. Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. The Board of Directors of Shire plc (Shire) announced on…

Analyst Activity – BTIG Research Reiterates Buy on Shire PLC (NASDAQ:SHPG)

Analyst Ratings For Shire PLC (NASDAQ:SHPG) Today, BTIG Research reiterated its Buy rating on Shire PLC (NASDAQ:SHPG) with a price target of $242.00. There are 3 hold ratings, 23 buy ratings on the stock. The current consensus rating on Shire PLC (NASDAQ:SHPG) is Buy (Score: 2.88) with a consensus target price of $223.07 per share, a potential 32.27% upside. Some recent analyst ratings include…

SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other Events

SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other EventsItem 8.01. Other Events Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein. Item 9.01. Financial Statements and Exhibits (d) Exhibits. The following exhibit is furnished herewith: 99.1       Press Release dated December 19, 2016     About SHIRE PLC (NASDAQ:SHPG)

Shire PLC (NASDAQ:SHPG) has learnt that an investor called TRC Capital Corporation is seeking to acquire as many as 1 million of its American Depositary Shares (ADSs). TRC Capital is trying to acquire the shares through a mini-tender offer. However, Shire is not happy with what TRC Capital is trying to do and has urged holders of its ADSs not to accept the investor’s offer.

The mini-tender offer

TRC Capital is paying $182.75 in cash for each ADS of Shire. A single ADS represents three ordinary shares of Shire, which means that if TRC Capital manages to acquire 1 million ADSs, it would end up owning about 0.33% of Shire’s outstanding ordinary shares.

Shire has said that it has nothing to do with TRC Capital’s mini-tender offer and it goes ahead to call it an unsolicited offer that it cannot recommend to holders of its ADS.

Why is Shire fighting TRC Capital’s offer?

The reason Shire is warning holders of its ADSs against TRC Capital’s offer is that it believes that the offer doesn’t offer any meaningful value to them. For instance, Shire says that the $182.75 per ADS price that TRC Capital is offering is nearly 5% below the closing price of its ADSs just a day before the mini-tender commenced.

Therefore, Shire believes that TRC Capital is trying to acquire its shares at price that is below the market, thus denying holders of the shares the opportunity to generate maximum value from their holding.

The other reason Shire is not endorsing TRC Capital’s mini-tender is that it comes with strings attached. For instance, the investor says in the tender documents that it holds the rights to terminate the offer if the market price of Shire’s ADSs fall from their closing price on July 15.

The fact that TRC Capital has launched a tender offer that would only see it acquire less than 5% of outstanding shares of Shire also makes the company suspicious of the mini-tender.

Fast Track designation

Shire’s caution against TRC Capital’s mini-tender offer comes at a time when the FDA has granted Fast Track designation for the company’s drug candidate called SHP626 (volixibat). The drug is being developed as a treatment for a liver condition known as nonalcoholic steatohepatitis (NASH).

In its attempts to expand its gastrointestinal drug portfolio, Shire PLC (ADR) (NASDAQ:SHPG) confirmed that it has purchased the rights to PF-00547659, the experimental inflammatory bowel disease (IBD) drug from Pfizer, Inc. (NYSE:PFE). According to Howard Mayer, Shire Head of Clinical Development, the licensing deal is consistent with the company’s commitment to designing GI treatments for small patient groups. However, the companies did not disclose further details about the deal.

PF-00547659 is specifically developed to target mucosal addressin cell adhesion molecule 1 (MAdCAM-1), a gastrointestinal endothelial adhesion molecule. It shares a similar mechanism of action with Entyvio and Tysabri, the drugs from Takeda Pharmaceutical Co. Ltd. (ADR) (OTCMKTS:TKPYY) and Biogen, Inc. (NASDAQ:BIIB) respectively.

The drug has already undergone Phase I and Phase II trials and has shown positive results for treating Crohn’s disease and ulcerative colitis in a trial of nearly 700 patients.

Crohn’s and ulcerative colitis are two of the most life-threatening IBD conditions that are characterized by fatigue, weight loss, inflamed intestines, severe stomach pains, rectal bleeding, and other related symptoms.

Those who received the IBD drug in the trial had higher mucosal healing, remission, and response rates by the 12th week than those who received a placebo.

Meanwhile, in the study involving CD patients, the subjects did not show any evidence of infection. In 2015, Pfizer clarified that the drug has no effect on the central nervous system’s immune surveillance like that of Tysabri.

A Phase III trial is expected to begin following consultation with global regulators.

GI Treatments

This week, Shire has also received a breakthrough designation from the US Food and Drug Administration for its GI drugs SHP621 and SHP625. The pharmaceutical giant has Vyvanse, a binge-eating disorder drug on the market already, and Gattex, a short bowel syndrome treatment.

Numerous IBD treatments are already available in the market today. However, the patents of many of these IBD drugs are expected to expire in the next few years.

Pfizer, on the other hand, is maintaining its focus on Xeljanz, a new rheumatoid arthritis drug, and on PF-04236921, another CD drug currently in the works.

New Post has been published on http://www.stockmarketsdaily.com/is-there-value-for-investors-shire-plc-nasdaqshpg/18366/

Is there Value for Investors: Shire plc (NASDAQ:SHPG)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Shire plc (NASDAQ:SHPG) [Trend Analysis] a company in the Drug Manufacturers – Major industry which traders have been highly interested in of late, to assess if it provides value for investors considering buying or selling it. Currently Shire plc is trading at $209.00 after moving down -1.91% in the previous day of trading.

SHPG is trading with a trailing 12 month P/E multiple of 13.53 and an estimated forward P/E multiple of 16.01. The stock has an estimated 5 year annual growth of 13.26% and a PEG multiple of 1.02.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Shire plc is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of SHPG. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of SHPG being 1.02, we consider Shire plc to likely be priced at fair value.

This analysis means that value buyers who do not currently hold Shire plc (NASDAQ:SHPG) should probably look for better value alternatives and investors currently holding the stock should either continue to hold or sell and look for alternatives.

New Post has been published on http://www.stockmarketsdaily.com/nearing-buy-territory-shire-plc-nasdaqshpg/12984/

Nearing Buy Territory: Shire plc (NASDAQ:SHPG)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Shire plc (NASDAQ:SHPG) a company in the Healthcare industry getting a lot of share market attention at present, to assess if it provides value for investors considering buying or selling it. Currently Shire plc is trading at $254.32 after moving up 2.93% in the previous day of trading. [Trend Analysis]

SHPG is trading with a trailing 12 month P/E multiple of 15.23 and an estimated forward P/E multiple of 19.21. The stock has an estimated 5 year annual growth of 14.23% and a PEG multiple of 1.07.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Shire plc is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of SHPG. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of SHPG being 1.07, we consider Shire plc to likely be priced at fair value.

This analysis means that value buyers who do not currently hold Shire plc (NASDAQ:SHPG) should probably look for better value alternatives and investors currently holding the stock should either continue to hold or sell and look for alternatives.

New Post has been published on http://www.stockmarketsdaily.com/shire-plc-underpriced-nasdaqshpg/8996/

Biopharma Research: Shire plc (NASDAQ:SHPG)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Shire plc (NASDAQ:SHPG) [Trend Analysis] a company in the biopharma industry which lately stock market players have been interested in, to assess if it provides value for investors considering buying or selling it. Currently Shire plc is trading at $233.71 after moving up 7.12% in the previous day of trading.

SHPG is trading with a trailing 12 month P/E multiple of 21.82 and an estimated forward P/E multiple of 20.41. The stock has an estimated 5 year annual growth of 12.83% and a PEG multiple of 1.70.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Shire plc is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of SHPG. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of SHPG being 1.70, we consider Shire plc to likely be priced at fair value.

This analysis means that value buyers who do not currently hold Shire plc (NASDAQ:SHPG) should probably look for better value alternatives and investors currently holding the stock should either continue to hold or sell and look for alternatives.